[Characteristics of the carcinogenic action of dibutylnitrosamine].
D000230:Adenocarcinoma / Q000139:chemically induced / Q000473:pathology; D000818:Animals; D002082:Butylamines / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced / Q000473:pathology; D004938:Esophageal Neoplasms / Q000139:chemically induced / Q000473:pathology; D005260:Female; D007279:Injections, Subcutaneous; D008113:Liver Neoplasms / Q000139:chemically induced / Q000473:pathology; D008175:Lung Neoplasms / Q000139:chemically induced / Q000473:pathology; D008297:Male; D009602:Nitrosamines / Q000494:pharmacology*; D010212:Papilloma / Q000139:chemically induced / Q000473:pathology; D051381:Rats; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000473:pathology
D002082:Butylamines; D009602:Nitrosamines
Ob osobennostiakh kantserogennogo deistviia dibutilnitrozamina.